The estimated Net Worth of Christopher S. Boerner is at least $14.2 Million dollars as of 10 March 2024. Mr. Boerner owns over 54,638 units of Bristol-Myers Squibb Co stock worth over $6,305,476 and over the last 13 years he sold BMY stock worth over $2,187,041. In addition, he makes $5,741,650 as Executive Vice President and Chief Commercial Officer at Bristol-Myers Squibb Co.
Sign up
Mr. Boerner BMY stock SEC Form 4 insiders trading
Christopher has made over 18 trades of the Bristol-Myers Squibb Co stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 54,638 units of BMY stock worth $2,654,860 on 10 March 2024.
The largest trade he's ever made was exercising 59,111 units of Bristol-Myers Squibb Co stock on 10 March 2023 worth over $2,872,203. On average, Christopher trades about 12,559 units every 174 days since 2011. As of 10 March 2024 he still owns at least 129,769 units of Bristol-Myers Squibb Co stock.
You can see the complete history of Mr. Boerner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Boerner biography
Dr. Christopher S. Boerner, Ph.D., is Executive Vice President and Chief Commercial Officer of the Company. He most recently served as the Company’s head of international markets from October 2017 to August 2018. He joined the Company in February 2015 as head of the U.S. commercial organization and served in that role until October 2017. Prior to joining the Company, he was with Seattle Genetics, Inc., where he served as executive vice president of commercial from 2014 to 2015 and senior vice president of commercial from 2012 to 2014. Before joining Seattle Genetics, Mr. Boerner was with Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he worked at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin, director of Avastin franchise strategy and associate director of oncology market development.
What is the salary of Christopher Boerner?
As the Executive Vice President and Chief Commercial Officer of Bristol-Myers Squibb Co, the total compensation of Christopher Boerner at Bristol-Myers Squibb Co is $5,741,650. There are 3 executives at Bristol-Myers Squibb Co getting paid more, with Giovanni Caforio having the highest compensation of $18,767,300.
How old is Christopher Boerner?
Christopher Boerner is 49, he's been the Executive Vice President and Chief Commercial Officer of Bristol-Myers Squibb Co since 2018. There are 34 older and 1 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.
What's Christopher Boerner's mailing address?
Christopher's mailing address filed with the SEC is BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543.
Insiders trading at Bristol-Myers Squibb Co
Over the last 16 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius, and Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.
What does Bristol-Myers Squibb Co do?
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
What does Bristol-Myers Squibb Co's logo look like?
Complete history of Mr. Boerner stock trades at Seagen Inc and Bristol-Myers Squibb Co
Bristol-Myers Squibb Co executives and stock owners
Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include:
-
Giovanni Caforio,
Chairman of the Board, Chief Executive Officer -
Sandra Leung,
Executive Vice President, General Counsel -
Dr. Giovanni Caforio M.D.,
Chairman & CEO -
Christopher Boerner,
Executive Vice President and Chief Commercial Officer -
David Elkins,
Executive Vice President and Chief Financial Officer Member of the Leadership Team -
Rupert Vessey,
Executive Vice President, Research and Early Development Member of the Leadership Team -
Louis Schmukler,
Executive Vice President, President - Global Product Development and Supply -
David V. Elkins,
Exec. VP & CFO -
Rupert Vessey BCH, BM, DPHIL, M.A.,
Exec. VP and Pres of Research & Early Devel. -
Sandra Leung Esq.,
Exec. VP & Gen. Counsel -
Dr. Christopher S. Boerner,
Exec. VP & Chief Commercialization Officer -
Vicki Sato,
Lead Independent Director -
Matthew Emmens,
Independent Director -
Peter Arduini,
Independent Director -
Dinesh Paliwal,
Independent Director -
Theodore Samuels,
Independent Director -
Karen Vousden,
Independent Director -
Robert Bertolini,
Independent Director -
Gerald Storch,
Independent Director -
Phyllis Yale,
Independent Director -
Julia Haller,
Independent Director -
Michael Bonney,
Independent Director -
Derica Rice,
Independent Director -
Paula Price,
Independent Director -
Tim Power,
Vice President of Investor Relations -
Joseph Eid,
Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team -
Karen Santiago,
Senior Vice President, Corporate Controller -
Adam Dubow,
Senior Vice President, Chief Compliance Officer and Ethics Officer -
Paul von Autenried,
Chief Information Officer, Senior Vice President -
Elizabeth Mily,
Executive Vice President - Strategy & Business Development -
Kathryn Metcalfe,
Executive Vice President - Corporate Affairs Member of the Leadership Team -
Samit Hirawat,
Executive Vice President, Chief Medical Officer, Global Drug Development Member of the Leadership Team -
Nadim Ahmed,
Executive Vice President and President - Hematology -
John Elicker,
Executive Vice President of Investor Relations -
Ann Judge,
Chief Human Resource Officer, Senior Vice President Member of the Leadership Team -
Ann M. Powell Judge,
Exec. VP & Chief HR Officer -
Adam Dubow,
Sr. VP, Chief Compliance & Ethics Officer -
Timothy Power,
VP & Head of Investor Relations -
Paul von Autenried,
Exec. VP & Chief Information Officer -
Greg Meyers,
Exec. VP and Chief Digital & Technology Officer -
Jose Baselga,
Director -
Alan J Lacy,
Director -
Joseph C Caldarella,
VP & Financial Controller -
Anne Nielsen,
Chief Compliance & Ethics Off -
Laurie H M.D. Glimcher,
Director -
Michael Grobstein,
Director -
Togo D Jr West,
Director -
Emmanuel Blin,
SVP, Head of Commercialization -
Francis M Cuss,
SVP Dscvry & Exp Clinl Resrch -
Murdo Gordon,
SVP, Head of Worldwide Markets -
Thomas J. Jr. Lynch,
Director -
Karin Shanahan,
EVP, Glob. Prod. Dev. & Supply -
Lynelle Hoch,
President, Cell Therapy Org. -
Phil M Holzer,
SVP and Controller -
Ahn Amanda Poole,
EVP, Chief Human Resources -
Samuel J Moed,
SVP, Strat Plan & Analysis -
Michelle Weese,
EVP, Corporate Affairs -
Paul Biondi,
SVP, Head of Strategy & BD -
Charles A Bancroft,
EVP, Head of Integration -
Ann Powell,
EVP, Chief Human Resources -
Frances K Heller,
SVP, Business Development -
Brian Daniels,
SVP Global Development -
Elliot Sigal,
EVP, CSO & President R&D -
Beatrice J Cazala,
SVP Comm Ops & Pres GC Euro EM -
Robert T Zito,
SVP & Chief Comm Officer -
Jeremy M Levin,
SVP Strat Transactions -
R Sanders Williams,
Director -
Anthony C Hooper,
President US Pharmaceuticals -
Louis J Freeh,
Director -
Anthony A Mcbride,
SVP Human Resources -
De Notaristefani Carlo,
President, Tech Ops -
Leif Johansson,
Director -
John E Celentano,
SVP Strat & Productivity Trans -
Jean Marc Huet,
SVP & CFO -
James M Cornelius,
Chairman & CEO -
Lewis B Campbell,
Director -
Medina Manuel Hidalgo,
Director -
Benjamin Hickey,
President, RayzeBio Org. -
Gregory Scott Meyers,
EVP, Chief Digital & Tech Off. -
Sharon Greenlees,
SVP & Controller -
Deepak Bhatt,
Director -
Michael R. Mc Mullen,
Director -
Adam Lenkowsky,
EVP, Chief Commercial Officer -
Robert M Plenge,
EVP, Chief Research Officer -
Cari Gallman,
EVP, Corporate Affairs